Download PDF
1 / Pages

Other users also viewed these articles

Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis Alejandro Balsa; Petra Díaz del Campo Fontecha; Lucía Silva Fernández; José Valencia Martín; Virginia Nistal Martínez; Fernando León Vázquez; M. Vanesa Hernández Hernández; Héctor Corominas; Rafael Cáliz Cáliz; José María Aguado García; Gloria Candelas Rodríguez; Nora Ibargoyen Roteta; Arturo Martí Carvajal; M. Nieves Plana Farras; Janet Puñal Riobóo; Hye Sang Park; Yolanda Triñanes Pego; Virginia Villaverde García;
Reumatol Clin. 2023;19:533-48
Practical aspects of biological throught levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis José Rosas; María Martín-López; Teresa Otón; Alejandro Balsa; Jaime Calvo-Alén; Raimon Sanmartí; Jesús Tornero; Loreto Carmona;
Reumatol Clin. 2020;16P2:378-85
Fibromyalgia with elevated rheumatoid factor is associated with poor therapeutic response but not with progression to rheumatoid arthritis. Prospective cohort study Freddy Liñán Ponce; Juan Leiva Goicochea; David Sevilla Rodríguez; Elmer Hidalgo Bravo; Ginna Obregón Atanacio; Inés Loyola Macalapú; Paola Jáuregui Rojas; Jackeline Yampufe Canani;
Reumatol Clin. 2024;20:459-62